System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ebrahim Variava is an expert in Infectiology at Perinatal HIV Research Unit (South Africa). As of October 2026, ScienceLeadR ranks Ebrahim Variava in the top 1% of experts worldwide for Tuberculosis, Pulmonary. Ebrahim Variava has authored 184 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 4 of them ongoing. SLR score: 642 (community average: 125). How the SLR is computed.

LeadR Profile

Ebrahim Variava Perinatal HIV Research Unit South Africa
642 ScienceLeadR Reputation 642

Unlock

Register Login
Network Map

Infectiology

Subspecialties: Public Health - Pulmonology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2002 - 2030
Source: PubMed

Perinatal HIV Research Unit

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 184

Citations

Citations: 5 359 1st author: 5 Last author: 23 Unique author: 2

Main journals

PLoS One 15
South Afr J HIV Med 10
Clin Infect Dis 9
Influenza Other Respir Viruses 8
Emerg Infect Dis 7

Best Journals

Lancet Infect Dis 4
N Engl J Med 2
Lancet Glob Health 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
High Mortality in Adults With Community-Acquired Pneumonia Admitted to Hospitals in South Africa Before and During the COVID-19 Pandemic, Stratified by HIV Serostatus and Viral Load: Data From a Prospective Cohort Study (2019-2021).
PMID 42871835 — mortality, cohort studies, viral load, cause of death, signs and symptoms, covid-19, pneumonia, tuberculosis, risk factors, pandemics, community-acquired pneumonia		Open Forum Infect Dis20260
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial.
PMID 42231943 — treatment failure, drug-related side effects and adverse reactions, hiv, therapeutics, pediatrics, child, dolutegravir		Open Forum Infect Dis20260
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.
PMID 42214407 — tuberculosis, pulmonary, safety, pharmaceutical preparations, drug-related side effects and adverse reactions, sputum, tuberculosis, research, therapeutics, isoniazid, communicable diseases, rifampin		Lancet Infect Dis20260
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial.
PMID 41967904 — treatment failure, hiv, therapeutics, communicable diseases, child, dolutegravir		Clin Infect Dis20260
SAHCS Guideline for the prevention, diagnosis and management of cryptococcal disease among persons living with HIV: Update to induction treatment for cryptococcal meningitis.
PMID 41960304 — meningitis, hiv, meningitis, cryptococcal, diagnosis, therapeutics		South Afr J HIV Med20260

Clinical Studies 14

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 4
Phase 2/Phase 3 4
N/A 3
Phase 3 3

By status:

Completed 10
Recruiting 2
Active not recruiting 1
Not yet recruiting 1

By type:

Interventional 14

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 2
multicentricup10 9

Main Topics

Cohort/Consortium Investigators 5

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A 6 Month MDR END Plus Regimen for Rifampicin Resistant Tuberculosis
NCT07675954 — clinical protocols, levofloxacin, genes, mdr, tuberculosis, multidrug-resistant, pharmaceutical preparations, clinical reasoning, aftercare, tuberculosis, body weight, therapeutics, rifampin, antitubercular agents, pyrazinamide		Phase 3Not yet recruiting2026
Sorfequiline based Regimens in Adults With Newly Diagnosed Drug sensitive Pulmonary TB
NCT07672405 — tuberculosis, pulmonary, safety, pharmaceutical preparations, multiple chronic conditions, linezolid, tablets, tuberculosis, therapeutics		Phase 2Recruiting2026
Remote Ischaemic Conditioning in STEMI Patients in AFRICA
NCT04813159 — mortality, blood, myocardial infarction, heart failure, heart, blood pressure, myocardial reperfusion injury, inflation, economic, st elevation myocardial infarction, reperfusion, reperfusion injury, myocardial reperfusion, conditioning, psychological, ischemia		N/ARecruiting2022
DTG 3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to 15 Years Old
NCT04337450 — pharmaceutical preparations, lamivudine, tablets, nucleosides, rna-directed dna polymerase, maintenance, aged, hiv, peptide hydrolases, protease inhibitors, hiv infections, reverse transcriptase inhibitors, infections, child, integrases, dolutegravir		Phase 2/Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS